PT - JOURNAL ARTICLE AU - Schmidt, Alec J. AU - García, Yury AU - Pinheiro, Diego AU - Reichert, Tom AU - Nuño, Miriam A. TI - Using Non-Pharmaceutical Interventions and High Isolation of Asymptomatic Carriers to Contain the Spread of SARS-CoV-2 in Nursing Homes AID - 10.1101/2021.01.22.21249308 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.22.21249308 4099 - http://medrxiv.org/content/early/2021/01/25/2021.01.22.21249308.short 4100 - http://medrxiv.org/content/early/2021/01/25/2021.01.22.21249308.full AB - Objective Using a pandemic influenza model modified for COVID-19, this study investigated the degree of control over pre-symptomatic transmission that common non-pharmaceutical interventions (NPIs) would require to reduce the spread in long-term care facilities.Methods We created a stochastic compartmental SEIR model with Poisson-distributed transition states that compared the effect of R0, common NPIs, and isolation rates of pre-symptomatic carriers primarily on attack rate, peak cases, and timing in a 200-resident nursing home. Model sensitivity was assessed with 1st order Sobol’ indices.Results The most rigorous NPIs decreased the peak number of infections by 4.3 and delayed the peak by 9.7 days in the absence of pre-symptomatic controls. Reductions in attack rate were not likely, even with rigorous application of all defined NPIs, unless pre-symptomatic carriers were identified and isolated at rates exceeding 76%. Attack rate was most sensitive to the pre-symptomatic isolation rate (Sobol’ index > 0.7) and secondarily to R0.Conclusions Common NPIs delayed and reduced epidemic peaks. Reducing attack rates ultimately required efficient isolation of pre-symptomatic cases, including rapid antigen tests on a nearly daily basis. This must be accounted for in testing and contact tracing plans for group living settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by a Seed Fund Award 2020-0000000022 from CITRIS and the Banatao Institute at the University of California. No third-party support was provided for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mathematical modeling paper; exempt from IRB review by the UC Davis Office of Research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full MATLAB code and all required materials to replicate the simulations from this mathematical modeling paper are publicly available at https://doi.org/10.5281/zenodo.4073575 https://doi.org/10.5281/zenodo.4073575 COVID-19Coronavirus Disease 2019EUAEmergency Use ActFDAFood and Drug AdministrationGSAGeneralized Sensitivity AnalysisLTCFLong-Term Care FacilityNPINon-Pharmaceutical InterventionPCRPolymerase Chain ReactionPPEPersonal Protective EquipmentSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SEIRSusceptible Exposed Infected RecoveredWHOWorld Health Organization